AMSTERDAM, June 23 /PRNewswire/ --

- Ready to Implement CrossRef's Plagiarism Detection Software After Successful Pilot

Elsevier, the leading publisher of science, technology and medical information announced today that it will implement CrossCheck, the plagiarism detection service offered by CrossRef in collaboration with iParadigms. With plagiarism a growing problem for journal editors, Elsevier has invested in CrossCheck to develop, pilot and implement, a single database of published articles enabling publishers to easily verify the originality of submitted and published work.

After a successful six months pilot with eight leading publishers, Elsevier is now in the process of integrating CrossCheck into its editorial workflows as part of its efforts to support the peer review process and assist the scientific community in all aspects of publishing ethics. Elsevier will contribute nearly nine million journal articles to the CrossCheck database, which is launching with a commitment of over 20 million journal articles from publishers including the Association for Computing Machinery, American Society of Neuroradiology, BMJ Publishing Group, Elsevier, Institute of Electrical & Electronics Engineers, International Union of Crystallography , The Journal of the American Medical Association, Nature Publishing Group, Oxford University Press, Sage, Informa UK (Taylor & Francis), and Wiley Blackwell.

"By creating a pooled database of articles from multiple publishers and tested tools, we can provide assistance to the scholarly community on an unprecedented scale," commented Martin Tanke, Elsevier's Managing Director of S&T Journal Publishing, "CrossRef has taken the principles of publisher collaboration far beyond reference linking. CrossCheck, combined with our recently launched Publishing Ethics Resource Kit and full journal membership in COPE (Committee on Publishing Ethics) further reinforce our commitment."

"CrossRef took the initiative to create this co-operative publisher service, which we greatly appreciate. This is a tremendous development and we are delighted that this collaboration has been so fruitful," said Karen Hunter, Senior Vice President Global Academic & Customer Relations and Elsevier's CrossRef Board member, "The iParadigms software is impressive and we are look forward to working with them."

John Barrie, Ph.D, president and CEO of iParadigms, LLC added, "Our customers, especially academic ones, have been asking for more medical and science content for checking the originality of work destined for publication. Elsevier's adoption of CrossCheck powered by iThenticate lets us leverage their vast, industry-leading content to significantly enhance the effectiveness of our originality checking services. Likewise, Elsevier will leverage the CrossCheck and iParadigms database which makes for a powerful alliance and one that is extremely beneficial to our network of institutional subscribers."

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (, MD Consult (, Scopus (, bibliographic databases, and online reference works.

Elsevier ( is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (, a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Contact: Ylann Schemm, Phone: +31-20-485-2025, E-mail:

Contact: Ylann Schemm, Phone: +31-20-485-2025, E-mail: